Cyclacel
Investors & Media

News

All Releases
View Summary Cyclacel Pharmaceuticals to Release First Quarter 2015 Financial Results
May 5, 2015
PDF 13.4 KB Add to Briefcase
View Summary Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds
Apr 20, 2015
PDF 23.5 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Mar 24, 2015
PDF 27.3 KB Add to Briefcase
View Summary Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015
Mar 20, 2015
PDF 12.6 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2014 Financial Results
Mar 17, 2015
PDF 13.4 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Mar 4, 2015
PDF 14.6 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
Mar 3, 2015
PDF 14.4 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
Feb 3, 2015
PDF 11.1 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference
Jan 6, 2015
PDF 11.1 KB Add to Briefcase
View Summary Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis
Dec 16, 2014
PDF 15.5 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Third Quarter 2014 Financial Results
Nov 11, 2014
PDF 24.7 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release 2014 Third Quarter Financial Results
Nov 4, 2014
PDF 13.2 KB Add to Briefcase
View Summary Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the Seamless Phase 3 Trial of Sapacitabine in AML
Oct 9, 2014
PDF 11.3 KB Add to Briefcase
View Summary Cyclacel to Present at BioCentury's Newsmakers in the Biotech Industry Conference
Sep 19, 2014
PDF 10.6 KB Add to Briefcase
View Summary Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements
Sep 18, 2014
PDF 14.2 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
Sep 11, 2014
PDF 13.3 KB Add to Briefcase
View Summary Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting
Sep 10, 2014
PDF 13.6 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at 16th Rodman & Renshaw Annual Global Investment Conference
Sep 2, 2014
PDF 10.7 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results
Aug 12, 2014
PDF 24.0 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release 2014 Second Quarter Financial Results
Aug 6, 2014
PDF 13.0 KB Add to Briefcase
Showing 41-60 of 339 Page: 1 2 3 4 5 6 7 ... 17  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Investors & Media